ПЕРВАЯ ЛИНИЯ ТЕРАПИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ
- Авторы: Тимофеев ИВ1
-
Учреждения:
- Бюро по изучению рака почки, Москва
- Выпуск: № 6 (2010)
- Страницы: 46-49
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/278357
- ID: 278357
Цитировать
Полный текст
Аннотация
Представлены обнадеживающие результаты рандомизированных исследований эффективности 5 различных таргетных препаратов (сунитиниб, сорафениб, темзиролимус, пазопаниб и бевацизумаб), применяемых в первой линии терапии метастатического почечно-клеточного рака. При внедрении новых препаратов в повседневную практику врача особое внимание должно быть уделено стандартизации подходов к оказанию медицинской помощи, согласно критериям эффективности.
Список литературы
- Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
- Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35.
- Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96.
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24.
- Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients. J Clin Oncol 2009;27(22):3584-90.
- Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10(8):757-63.
- Tsimafeyeu IV. Salvage therapy with sunitinib malate in metastatic renal cell carcinoma patients. EMUC 2009;130:91.
- Yang ОС, Haworth L, Sherry RM, et al. A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. N Engl J Med 2003;349:427-34.
- Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11.
- Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha 2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:15.
- Rini BI, Halabi S, Rosenberg J, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27:18.
- Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855-61.
- Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11(15):5472-80.
- Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72.
- Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 2007;25(18):25.
- Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81.
- Sternberg C, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009;27(15):5021.
Дополнительные файлы
